Advanced Filters
noise

a, a N Clinical Trials

A listing of a, a N clinical trials actively recruiting patients volunteers.

Found 11,120 clinical trials
A Anthony Sung, MD

A Phase 2 Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation

This is a research study to compare the well-being (caregiver strain index) of caregivers of patients receiving home vs standard care after autologous hematopoietic stem cell transplant.

18 - 80 years of age All Phase N/A
R Richard Nicholas, PhD

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

In multiple sclerosis (MS) cells of the immune system attack the brain causing tissue damage. In secondary progressive MS (SPMS) these repeated immune attacks have stopped but despite this new damage continues to appear. TSPO is a protein found in the brain and cells of the immune system, whose levels …

35 - 65 years of age All Phase N/A
A Austin Stone, MD, PhD

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at …

25 - 50 years of age All Phase N/A
H Heather Tansksley, MOT, OTR/L

Slow Wave Sleep as a Biomarker of Rehabilitation-induced Cognitive Improvement in PD

The purpose of this study is to investigate the effects of exercise rehabilitation on cognition and to evaluate slow wave sleep (SWS) as a biomarker and mediator of response to rehabilitation-induced improvement in cognitive performance among persons with Parkinson's disease (PwP), with the ultimate goal of maximizing rehabilitation efficacy at …

45 - 100 years of age All Phase N/A
Q Qingyuan Zhang, Doctor

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), an enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic …

18 - 75 years of age All Phase 1
Y Yvonne Taul

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

This is a prospective, randomized study designed to compare genotype-guided dosing to usual care in patients with pancreas cancer and colorectal cancer who are UGT1A1 intermediate metabolizers (1/28) (heterozygotes) and usual UGT metabolizers (1/1). All patients will be assessed for UGT1A1 genotype at screening and those with intermediate or usual …

18 years of age All Phase N/A
T Terence Ho, MB MSc

Sputum-guided Treatment With Comprehensive Care Management in COPD - A Randomized-controlled Trial

Chronic obstructive pulmonary disease (COPD) is a lung condition affecting 1 in 6 Canadians and does not have a cure. Flare-ups of COPD are the most common reason someone goes to hospital in Canada. This is made worse because within 30-days of having a flare-up, 1 in 5 patients will …

40 years of age All Phase N/A
J Justin P Gawaziuk, MSc

A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full …

18 years of age All Phase 1/2

The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots

Open labelled, virtual home based study to assess the test repeatability and the failure/rejection rate of the samples collected at home by participants.

18 - 80 years of age All Phase N/A

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .

18 - 75 years of age All Phase 1/2

Simplify language using AI